Supported by the American Society of Colon and Rectal Surgeons Limited Project Grant #078 A.M.M. Opinions expressed are those of the authors and not the American Society of Colon and Rectal Surgeons.
Individual health discount rate in patients with ulcerative colitis†
Article first published online: 16 NOV 2010
Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 17, Issue 6, pages 1328–1332, June 2011
How to Cite
Waljee, A. K., Morris, A. M., Waljee, J. F. and Higgins, P. D.R. (2011), Individual health discount rate in patients with ulcerative colitis. Inflamm Bowel Dis, 17: 1328–1332. doi: 10.1002/ibd.21515
- Issue published online: 10 MAY 2011
- Article first published online: 16 NOV 2010
- Manuscript Accepted: 5 SEP 2010
- Manuscript Received: 2 SEP 2010
- American Society of Colon and Rectal Surgeons Limited Project Grant. Grant Number: #078
- ulcerative colitis;
- discount rates;
- quality of life;
In cost-effectiveness analysis, discount rates are used in calculating the value of future costs and benefits. However, standard discount rates may not accurately describe the decision-making of patients with ulcerative colitis (UC). These patients often choose the long-term risks of immunosuppressive therapy over the short-term risks of colectomy, demonstrating very high discount rates for future health. In this study we aimed to measure the discount rate in UC patients and identify variables associated with the discount rate.
We surveyed patients with UC and patients who were postcolectomy for UC to measure their valuations of UC and colectomy health states. We used Standard Gamble (SG) and Time-Trade-Off (TTO) methods to assess current and future health state valuations and calculated the discount rate.
Participants included 150 subjects with UC and 150 subjects who were postcolectomy for UC. Adjusted discount rates varied widely (0%–100%), with an overall median rate of 55.0% (interquartile range [IQR] 20.6–100), which was significantly higher than the standard rate of 5%. Within the normal range of discount rates, patients' expected discount rate increased by 0.80% for each additional year of age, and female patients had discount rates that averaged ≈8% less than their age-matched counterparts and approached statistical significance.
The accepted discount rate of 5% grossly underestimates UC patients' preference for long-term over short-term risk. This might explain UC patients' frequent choice of the long-term risks of immunosuppressive medical therapy over the short-term risks of colectomy. (Inflamm Bowel Dis 2011;)